These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 34290972)
1. Preparing and assessing the physiochemical properties of curcumin niosomes and evaluating their cytotoxicity in 3T3 and MCF-7 cell lines. Ashraf Ganjooei N; Ohadi M; Mostafavi SMA; Behnam B; Pardakhty A Avicenna J Phytomed; 2021; 11(4):417-427. PubMed ID: 34290972 [TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of hydrophilic and hydrophobic drugs into niosomal nanocarrier for enhanced breast cancer therapy: In silico and in vitro studies. Amiri S; Pashizeh F; Moeinabadi-Bidgoli K; Eyvazi Y; Akbari T; Salehi Moghaddam Z; Eskandarisani M; Farahmand F; Hafezi Y; Nouri Jevinani H; Seif M; Mousavi-Niri N; Chiani M; Tavakkoli Yaraki M Environ Res; 2023 Dec; 239(Pt 2):117292. PubMed ID: 37806480 [TBL] [Abstract][Full Text] [Related]
3. A comparative study on biopharmaceutical function of curcumin and miR-34a by multistimuli-responsive nanoniosome carrier: Abtahi NA; Naghib SM; Haghiralsadat F; Akbari Edgahi M; Askari E Front Mol Biosci; 2022; 9():1043277. PubMed ID: 36325275 [TBL] [Abstract][Full Text] [Related]
5. Curcumin Niosomes Prepared from Proniosomal Gels: In Vitro Skin Permeability, Kinetic and In Vivo Studies. Shehata TM; Ibrahim MM; Elsewedy HS Polymers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806659 [TBL] [Abstract][Full Text] [Related]
6. A comparison study between doxorubicin and curcumin co-administration and co-loading in a smart niosomal formulation for MCF-7 breast cancer therapy. Saharkhiz S; Zarepour A; Nasri N; Cordani M; Zarrabi A Eur J Pharm Sci; 2023 Dec; 191():106600. PubMed ID: 37802230 [TBL] [Abstract][Full Text] [Related]
7. Empowering Cancer Therapy: Comparing PEGylated and Non-PEGylated Niosomes Loaded with Curcumin and Doxorubicin on MCF-7 Cell Line. Saharkhiz S; Zarepour A; Zarrabi A Bioengineering (Basel); 2023 Oct; 10(10):. PubMed ID: 37892889 [TBL] [Abstract][Full Text] [Related]
8. Anticancer evaluation of methotrexate and curcumin-coencapsulated niosomes against colorectal cancer cell lines. Mousazadeh N; Gharbavi M; Rashidzadeh H; Nosrati H; Danafar H; Johari B Nanomedicine (Lond); 2022 Feb; 17(4):201-217. PubMed ID: 35037483 [No Abstract] [Full Text] [Related]
10. Apoptosis Induction, Cell Cycle Arrest and Anti-Cancer Potential of Tamoxifen-Curcumin Loaded Niosomes Against MCF-7 Cancer Cells. Fatemizadeh M; Tafvizi F; Shamsi F; Amiri S; Farajzadeh A; Akbarzadeh I Iran J Pathol; 2022; 17(2):183-190. PubMed ID: 35463725 [TBL] [Abstract][Full Text] [Related]
11. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Ghafelehbashi R; Akbarzadeh I; Tavakkoli Yaraki M; Lajevardi A; Fatemizadeh M; Heidarpoor Saremi L Int J Pharm; 2019 Oct; 569():118580. PubMed ID: 31374239 [TBL] [Abstract][Full Text] [Related]
12. Nanosized paclitaxel-loaded niosomes: formulation, in vitro cytotoxicity, and apoptosis gene expression in breast cancer cell lines. Pourmoghadasiyan B; Tavakkoli F; Beram FM; Badmasti F; Mirzaie A; Kazempour R; Rahimi S; Larijani SF; Hejabi F; Sedaghatnia K Mol Biol Rep; 2022 May; 49(5):3597-3608. PubMed ID: 35235156 [TBL] [Abstract][Full Text] [Related]
13. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study. Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236 [TBL] [Abstract][Full Text] [Related]
14. In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment. Ahmadi S; Seraj M; Chiani M; Hosseini S; Bazzazan S; Akbarzadeh I; Saffar S; Mostafavi E Int J Nanomedicine; 2022; 17():6233-6255. PubMed ID: 36531115 [TBL] [Abstract][Full Text] [Related]
15. Niosomal delivery of simvastatin to MDA-MB-231 cancer cells. Akbarzadeh I; Saremi Poor A; Yaghmaei S; Norouzian D; Noorbazargan H; Saffar S; Ahangari Cohan R; Bakhshandeh H Drug Dev Ind Pharm; 2020 Sep; 46(9):1535-1549. PubMed ID: 32808813 [TBL] [Abstract][Full Text] [Related]
16. Enhanced anti-cancer effect of artemisinin- and curcumin-loaded niosomal nanoparticles against human colon cancer cells. Firouzi Amandi A; Jokar E; Eslami M; Dadashpour M; Rezaie M; Yazdani Y; Nejati B Med Oncol; 2023 May; 40(6):170. PubMed ID: 37156929 [TBL] [Abstract][Full Text] [Related]
17. Nonionic surfactant-based vesicular system for transdermal drug delivery. Ghanbarzadeh S; Khorrami A; Arami S Drug Deliv; 2015 Dec; 22(8):1071-1077. PubMed ID: 24400680 [TBL] [Abstract][Full Text] [Related]
18. Formulation and Characterization of Curcumin Niosomes: Antioxidant and Cytotoxicity Studies. Ghumman SA; Ijaz A; Noreen S; Aslam A; Kausar R; Irfan A; Latif S; Shazly GA; Shah PA; Rana M; Aslam A; Altaf M; Kotwica-Mojzych K; Bin Jardan YA Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895877 [TBL] [Abstract][Full Text] [Related]
19. Optimization, physicochemical characterization, and antimicrobial activity of a novel simvastatin nano-niosomal gel against E. coli and S. aureus. Akbarzadeh I; Keramati M; Azadi A; Afzali E; Shahbazi R; Chiani M; Norouzian D; Bakhshandeh H Chem Phys Lipids; 2021 Jan; 234():105019. PubMed ID: 33232724 [TBL] [Abstract][Full Text] [Related]
20. Curcumin-loaded mixed micelles: preparation, optimization, physicochemical properties and cytotoxicity in vitro. Duan Y; Wang J; Yang X; Du H; Xi Y; Zhai G Drug Deliv; 2015 Jan; 22(1):50-7. PubMed ID: 24417664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]